Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896295 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Momenta Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT03896295 is a Phase 2 study that was terminated before completion, run by Momenta Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT03896295, a Phase 2 study, was terminated before completion, sponsored by Momenta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
Interventions
- DRUG M281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-08-06 |
| Est. Completion | 2020-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896295
The ClinicalTrials.gov registry entry for NCT03896295 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M281 is the first listed.
NCT03896295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03896295 about?
NCT03896295 is a clinical study titled "An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis". The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
What is the current status of trial NCT03896295?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2019-08-06. Estimated completion is 2020-12-09.
What interventions are being tested in trial NCT03896295?
The interventions under investigation include: M281 (DRUG).
Who is sponsoring clinical trial NCT03896295?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.